Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Fell Today

By Joe Tenebruso – Updated Aug 31, 2020 at 4:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus vaccine maker is being investigated for failing to disclose government funding in its patent applications.

What happened

Shares of Moderna (MRNA 2.12%) declined by 3.9% on Monday. The biotech company's vaccine patent portfolio is reportedly being probed by the U.S. Department of Defense for a lack of proper funding disclosures, according to the Financial Times

So what

The Defense Department investigation comes after a report by patient advocacy group Knowledge Ecology International, which claimed that Moderna failed to disclose the grants it received from the Defense Advanced Research Projects Agency (DARPA) in its patent applications -- including those of its coronavirus vaccine candidate -- as required by federal law.

A person is using a magnifying glass to look more closely at a document.

The U.S. DoD is scanning Moderna's patent filings. Image source: Getty Images.

Moderna, meanwhile, denies any wrongdoing. "The company believes it has complied with applicable patent reporting requirements regarding patent filings, including as they relate to the DARPA program," Moderna spokesperson Ray Jordan told Bloomberg. 

Now what

It's unclear what penalties Moderna would face if it's found to have failed to make the proper disclosures in its patent filings. But investors don't like uncertainty, and some chose to sell their shares on Monday.

Recent reports that Moderna's experimental vaccine would also need to be stored at ultra-low temperatures, which could make distribution of the potential vaccine more difficult, likely also contributed to the decline. 

Still, Moderna is pressing forward. The company said last week it's in negations with Japan's Ministry of Health, Labour, and Welfare for the potential sale of 40 million doses of its COVID-19 vaccine candidate. 

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$122.23 (2.12%) $2.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.